Monte Rosa Therapeutics earnings were $6.2M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest GLUE earnings report on Mar 31, 2025 announced Q1 2025 earnings of $46.9M, up 248.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, GLUE reported annual earnings of -$72.7M, with -46.3% growth. The next GLUE earnings date is Aug 7, 2025.
Monte Rosa Therapeutics Earnings Reports & History FAQ
What were Monte Rosa Therapeutics's earnings last quarter?
Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q1 2025 earnings per share (EPS) of $0.57, up 207.55% year over year. Total GLUE earnings for the quarter were $46.89 million. In the same quarter last year, Monte Rosa Therapeutics's earnings per share (EPS) was -$0.53.
When does Monte Rosa Therapeutics report earnings?
The next GLUE earnings date is Invalid Date. Add GLUE to your watchlist to be reminded of Monte Rosa Therapeutics's next earnings date.
Is Monte Rosa Therapeutics profitable or losing money?
As of the last Monte Rosa Therapeutics earnings report, Monte Rosa Therapeutics is currently profitable. Monte Rosa Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $6.15 million, a 104.55% decrease year over year.
What was GLUE's earnings growth in the past year?
As of Monte Rosa Therapeutics's earnings date in Q3 2025, Monte Rosa Therapeutics's earnings has grown year over year. GLUE earnings in the past year totalled $6.15 million.
What are Monte Rosa Therapeutics's earnings expectations?
The current EPS estimate for Monte Rosa Therapeutics's earnings report in Invalid Date is -$0.38.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.